



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

Shilpa House # 12-6-214/A-1, Hyderabad Road,  
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

E-mail : info@vbsilpa.com Website : http://www.vbsilpa.com

CIN No. L85110KA1987PLC008739

Date: 14<sup>th</sup> August 2018

To The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G, Bandra Kurla complex, Bandra (E), Mumbai- 400 051
---	---

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Symbol : SHILPAMED and Scrip code 530549

We hereby inform you that the Board of Directors at their meeting held on 13.08.2018, has decided to promote 100% wholly owned subsidiary Company (since incorporated) for the business operations in US and North American Countries. The disclosure for the proposed Company are as follows:

S No	Particulars	Information
1	Name of the Target Entity, Details in brief size etc.	Shilpa Pharma Inc, USA
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No
3	Industry to which the entity being acquired belongs	Pharmaceutical Sector
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Not Applicable
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6	Indicative time period for completion of acquisition	1 month approximately
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired;	100 USD
9	Percentage of shareholding / control acquired and / or number of shares acquired;	100%



10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Got incorporated the target company through the representative of the Shilpa Medicare Limited on 30 <sup>th</sup> May 2018. Now the subscription shares held by the representative will be transferred to the Shilpa Medicare Limited  Country of presence: United States of America.
----	--	---

The Meeting was commenced at 11:00 A.M and ended at 2.30 P.M.

This is for your information and record.

Thanking you

**For Shilpa Medicare Limited**

  
**Madhusudhan Reddy**  
 Company Secretary & Compliance Officer

